» Articles » PMID: 31175329

Colorectal Carcinoma with Double Somatic Mismatch Repair Gene Inactivation: Clinical and Pathological Characteristics and Response to Immune Checkpoint Blockade

Abstract

Double somatic mismatch-repair-gene mutation/alteration is a recently recognized molecular mechanism that underlies microsatellite instability-high in some colorectal carcinomas. It remains to be determined whether and how microsatellite instability-high tumors with this molecular defect differ from their counterparts caused by other mechanisms, specifically, Lynch syndrome-associated and MLH1-promoter hypermethylated. In this study, we evaluated the clinical and pathological characteristics of a series of 15 double somatic mutation/alteration-associated microsatellite instability-high colorectal carcinomas identified from our genetics service and 68 such cases reported in the literature. We observed that these cases presented at an age similar to MLH1-promoter hypermethylated (n = 20) and microsatellite-stable (n = 39) cases but older than Lynch syndrome-associated cases (n = 20, p < 0.05). While these tumors simulated other microsatellite instability-high tumors in their prevalent right-sided location, they appeared to differ in TNM stages at presentation (73% stage III/IV versus 25% stage III/IV in other microsatellite instability-high tumors, p = 0.04). Histologically, 40% of them had a dominant solid growth pattern. Inter-tumoral heterogeneity was a striking feature, spanning the spectrum from medullary type (with a tumor-infiltrating-lymphocyte/high-power-field count as high as 59) to conventional-type with only few tumor-infiltrating-lymphocytes (1/high-power-filed). As a group, these tumors seemed less likely to show robustly high lymphocytic infiltration than other microsatellite instability-high tumors (only 20% had ≥10 tumor-infiltrating-lymphocytes/high-power-filed, whereas this rate in Lynch syndrome-associated and MLH1-promoter hypermethylated tumors was 60% and 75%, respectively). Three double somatic mutation/alteration-associated tumors were treated with a PD1/PD-L1 checkpoint inhibitor. While all three had an elevated tumor-mutation-burden (>47 mut/megabase), only one had tumor-infiltrating-lymphocytes >10/high-power-field, yet all three exhibited measurable response. In summary, microsatellite instability-high colorectal carcinomas caused by double somatic mismatch-repair-gene mutation/alteration may have varied clinical and pathological characteristics, and some may have relatively low tumor-infiltrating-lymphocytes; response to immune checkpoint inhibitors can be achieved in this group even when the lymphocytic infiltration is not abundant.

Citing Articles

Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors.

Ykema B, Breekveldt E, Carvalho B, van Wezel T, Meijer G, Kerst M Br J Cancer. 2022; 127(11):1991-1996.

PMID: 36088508 PMC: 9681876. DOI: 10.1038/s41416-022-01972-7.


Lynch Syndrome: From Carcinogenesis to Prevention Interventions.

Gambini D, Ferrero S, Kuhn E Cancers (Basel). 2022; 14(17).

PMID: 36077639 PMC: 9454739. DOI: 10.3390/cancers14174102.


Heterogeneity in the psychosocial and behavioral responses associated with a diagnosis of suspected Lynch syndrome in women with endometrial cancer.

Jonnagadla S, Joseland S, Saya S, Den Elzen N, Isbister J, Winship I Hered Cancer Clin Pract. 2022; 20(1):27.

PMID: 35840994 PMC: 9284782. DOI: 10.1186/s13053-022-00233-1.


Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.

Salewski I, Henne J, Engster L, Schneider B, Lemcke H, Skorska A Int J Mol Sci. 2021; 22(11).

PMID: 34206051 PMC: 8199186. DOI: 10.3390/ijms22115990.


Lynch Syndrome: Its Impact on Urothelial Carcinoma.

Lindner A, Schachtner G, Tulchiner G, Thurnher M, Untergasser G, Obrist P Int J Mol Sci. 2021; 22(2).

PMID: 33430305 PMC: 7825811. DOI: 10.3390/ijms22020531.


References
1.
Venderbosch S, Nagtegaal I, Maughan T, Smith C, Cheadle J, Fisher D . Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20(20):5322-30. PMC: 4201568. DOI: 10.1158/1078-0432.CCR-14-0332. View

2.
Rigter L, Snaebjornsson P, Rosenberg E, Atmodimedjo P, Aleman B, Ten Hoeve J . Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. Gut. 2018; 67(3):447-455. DOI: 10.1136/gutjnl-2016-312608. View

3.
Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J . OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017; 2017. PMC: 5586540. DOI: 10.1200/PO.17.00011. View

4.
Morak M, Heidenreich B, Keller G, Hampel H, Laner A, de la Chapelle A . Biallelic MUTYH mutations can mimic Lynch syndrome. Eur J Hum Genet. 2014; 22(11):1334-7. PMC: 4200426. DOI: 10.1038/ejhg.2014.15. View

5.
Fabrizio D, George Jr T, Dunne R, Frampton G, Sun J, Gowen K . Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J Gastrointest Oncol. 2018; 9(4):610-617. PMC: 6087857. DOI: 10.21037/jgo.2018.05.06. View